BLOOD ADVANCES Journal

publication venue for

Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies. 4:1917-1926. 2020
Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients 2021

International Standard Serial Number (ISSN)

2473-9529

Electronic International Standard Serial Number (EISSN)

2473-9537

journal abbreviation

BLOOD ADV